High levels of Epstein-Barr virus DNA in latently infected gastric adenocarcinoma

Laboratory Investigation

Volumn 89, Issue 1, 2009, Pages 80-90

  Ryan, Julie L ^a   Morgan, Douglas R ^b   Dominguez, Ricardo L ^c   Thorne, Leigh B ^b,d   Elmore, Sandra H ^d   Mino Kenudson, Mari ^e   Lauwers, Gregory Y ^e   Booker, Jessica K ^d   Gulley, Margaret L ^b,d  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Western Regional Hospital   (Honduras)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Epstein Barr virus; Gastric adenocarcinoma; Latency; Replication; Viral load

Indexed keywords

PROTEIN LMP1; PROTEIN LMP2; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN;

ARTICLE; CANCER INCIDENCE; CONTROLLED STUDY; DNA DETERMINATION; EPSTEIN BARR VIRUS; GENE AMPLIFICATION; GENE DELETION; GENE LOSS; GENETIC VARIABILITY; HISTOCHEMISTRY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH ADENOCARCINOMA; VIRUS LATENCY; VIRUS LOAD;

EID: 58149105749     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2008.103     Document Type: Article

References (68)

1. Correa P, Piazuelo MB, Camargo MC. The future of gastric cancer prevention. Gastric Cancer 2004;7:9-16.
2. Boussioutas A, Taupin D. Towards a molecular approach to gastric cancer management. Intern Med J 2001;31:296-303.
3. Henson DE, Dittus C, Younes M, et al. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. Arch Pathol Lab Med 2004;128:765-770.
4. Carrascal E, Koriyama C, Akiba S, et al. Epstein-Barr virus-associated gastric carcinoma in Cali, Colombia. Oncol Rep 2003;10:1059-1062.
5. Corvalan A, Koriyama C, Akiba S, et al. Epstein-Barr virus in gastric carcinoma is associated with location in the cardia and with a diffuse histology: a study in one area of Chile. Int J Cancer 2001;94:527-530.
6. Cho HJ, Kim JY, Yoo J, et al. Gastric carcinoma with lymphoid stroma: incidence of EBV and Helicobacter pylori infection. Appl Immunohistochem Mol Morphol 2003;11:149-152.
7. van Beek J, zur Hausen A, Klein Kranenbarg E, et al. EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol 2004;22:664-670.
8. Oda K, Koda K, Takiguchi N, et al. Detection of Epstein-Barr virus in gastric carcinoma cells and surrounding lymphocytes. Gastric Cancer 2003;6:173-178.
9. Pattle SB, Farrell PJ. The role of Epstein-Barr virus in cancer. Expert Opin Biol Ther 2006;6:1193-1205.
10. Gulley ML, Tang W. Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn 2008;10:279-292.
11. Koriyama C, Akiba S, Corvalan A, et al. Histology-specific gender, age and tumor-location distributions of Epstein-Barr virus-associated gastric carcinoma in Japan. Oncol Rep 2004;12:543-547.
12. Fukayama M, Chong JM, Kaizaki Y. Epstein-Barr virus and gastric carcinoma. Gastric Cancer 1998;1:104-114.
13. Lee HS, Chang MS, Yang HK, et al. Epstein-Barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with Epstein-Barr virus-negative carcinoma. Clin Cancer Res 2004;10:1698-1705.
14. Schneider BG, Gulley ML, Eagan P, et al. Loss of p16/CDKN2A tumor suppressor protein in gastric adenocarcinoma is associated with Epstein-Barr virus and anatomic location in the body of the stomach. Hum Pathol 2000;31:45-50.
15. Zur Hausen A, van Rees BP, van Beek J, et al. Epstein-Barr virus in gastric carcinomas and gastric stump carcinomas: a late event in gastric carcinogenesis. J Clin Pathol 2004;57:487-491.
16. Nishikawa J, Yanai H, Hirano A, et al. High prevalence of Epstein-Barr virus in gastric remnant carcinoma after Billroth-II reconstruction. Scand J Gastroenterol 2002;37:825-829.
17. Yamamoto N, Tokunaga M, Uemura Y, et al. Epstein-Barr virus and gastric remnant cancer. Cancer 1994;74:805-809.
18. Gulley ML. Molecular diagnosis of Epstein-Barr virus-related diseases. J Mol Diagn 2001;3:1-10.
19. Grinstein S, Preciado MV, Gattuso P, et al. Demonstration of Epstein-Barr virus in carcinomas of various sites. Cancer Res 2002;62:4876-4878.
20. Sixbey J. Epstein-Barr virus DNA loss from tumor cells and the geography of Burkitt's lymphoma. Epstein-Barr Virus Rep 2000;7:37-40.
21. Gan YJ, Razzouk BI, Su T, et al. A defective, rearranged Epstein-Barr virus genome in EBER-negative and EBER-positive Hodgkin's disease. Am J Pathol 2002;160:781-786.
22. Takeuchi H, Kobayashi R, Hasegawa M, et al. Detection of latent Epstein-Barr virus (EBV) DNA in paraffin sections of nasopharyngeal carcinomas expressing no EBV-encoded small RNAs using in situ PCR. Arch Virol 1997;142:1743-1756.
23. Chen PC, Pan CC, Yang AH, et al. Detection of Epstein-Barr virus genome within thymic epithelial tumours in Taiwanese patients by nested PCR, PCR in situ hybridization, and RNA in situ hybridization. J Pathol 2002;197:684-688.
24. Korabecna M, Ludvikova M, Skalova A. Molecular diagnosis of Epstein-Barr virus in paraffin-embedded tissues of tumors with abundant lymphoid infiltration. Neoplasma 2003;50:8-12.
25. Lauritzen AF, Hording U, Nielsen HW. Epstein-Barr virus and Hodgkin's disease: a comparative immunological, in situ hybridization, and polymerase chain reaction study. Apmis 1994;102:495-500.
26. Niedobitek G, Herbst H. In situ detection of Epstein-Barr virus and phenotype determination of EBV-infected cells. Methods Mol Biol 2006;326:115-137.
27. Delecluse HJ, Feederle R, O'Sullivan B, et al. Epstein-Barr virus-associated tumours: an update for the attention of the working pathologist. J Clin Pathol 2007;60:1358-1364.
28. Hennard C, Pfuhl T, Buettner M, et al. The antibody 2B4 directed against the Epstein-Barr virus (EBV)-encoded nuclear antigen 1 (EBNA1) detects MAGE-4: implications for studies on the EBV association of human cancers. J Pathol 2006;209:430-435.
29. Gulley ML, Pulitzer DR, Eagan PA, et al. Epstein-Barr virus infection is an early event in gastric carcinogenesis and is independent of bcl-2 expression and p53 accumulation. Hum Pathol 1996;27:20-27.
30. Hoshikawa Y, Satoh Y, Murakami M, et al. Evidence of lytic infection of Epstein-Barr virus (EBV) in EBV-positive gastric carcinoma. J Med Virol 2002;66:351-359.
31. Wang Y, Luo B, Yan LP, et al. Relationship between Epstein-Barr virus-encoded proteins with cell proliferation, apoptosis, and apoptosis-related proteins in gastric carcinoma. World J Gastroenterol 2005;11:3234-3239.
32. Luo B, Wang Y, Wang XF, et al. Expression of Epstein-Barr virus genes in EBV-associated gastric carcinomas. World J Gastroenterol 2005;11:629-633.
33. Andal N, Shanthi P, Krishnan KB, et al. The Epstein-Barr virus and gastric carcinoma. Indian J Pathol Microbiol 2003;46:34-36.
34. van Beek J, zur Hausen A, Kranenbarg EK, et al. A rapid and reliable enzyme immunoassay PCR-based screening method to identify EBV-carrying gastric carcinomas. Mod Pathol 2002;15:870-877.
35. Morgan DR, Dominguez RL, Keku TO, et al. Gastric cancer and the high combination prevalence of host cytokine genotypes and Helicobacter pylori in Honduras. Clin Gastroenterol Hepatol 2006;4:1103-1111.
36. Fenoglio-Presier C, Carneiro F, Correa P. Tumours of the stomach. In: Hamilton SR, Aaltonen LA (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Digestive System. IARC Press: Lyon France, 2000, pp 37-52.
37. Ryan JL, Fan H, Glaser SL, et al. Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma. J Mol Diagn 2004;6:378-385.
38. Ling PD, Vilchez RA, Keitel WA, et al. Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 2003;37:1244-1249.
39. Yanai H, Takada K, Shimizu N, et al. Epstein-Barr virus infection in noncarcinomatous gastric epithelium. J Pathol 1997;183:293-298.
40. Arikawa J, Tokunaga M, Tashiro Y, et al. Epstein-Barr virus-positive multiple early gastric cancers and dysplastic lesions: a case report. Pathol Int 1997;47:730-734.
41. Hungermann D, Muller S, Spieker T, et al. Low prevalence of latently Epstein-Barr virus-infected cells in chronic gastritis. Microsc Res Tech 2001;53:409-413.
42. Hirano A, Yanai H, Shimizu N, et al. Evaluation of Epstein-Barr virus DNA load in gastric mucosa with chronic atrophic gastritis using a real-time quantitative PCR assay. Int J Gastrointest Cancer 2003;34:87-94.
43. Imai S, Koizumi S, Sugiura M, et al. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci USA 1994;91:9131-9135.
44. Alipov G, Nakayama T, Nakashima M, et al. Epstein-Barr virus-associated gastric carcinoma in Kazakhstan. World J Gastroenterol 2005;11:27-30.
45. Vo QN, Geradts J, Gulley ML, et al. Epstein-Barr virus in gastric adenocarcinomas: association with ethnicity and CDKN2A promoter methylation. J Clin Pathol 2002;55:669-675.
46. Chan WY, Liu Y, Li CY, et al. Recurrent genomic aberrations in gastric carcinomas associated with Helicobacter pylori and Epstein-Barr virus. Diagn Mol Pathol 2002;11:127-134.
47. Saxena A, Nath Prasad K, Chand Ghoshal U, et al. Association of Helicobacter pylori and Epstein-Barr virus with gastric cancer and peptic ulcer disease. Scand J Gastroenterol 2008;43:669-674.
48. Kaye KM, Izumi KM, Li H, et al. An Epstein-Barr virus that expresses only the first 231 LMP1 amino acids efficiently initiates primary B-lymphocyte growth transformation. J Virol 1999;73:10525-10530.
49. Song YJ, Jen KY, Soni V, et al. IL-1 receptor-associated kinase 1 is critical for latent membrane protein 1-induced p65/RelA serine 536 phosphorylation and NF-kappaB activation. Proc Natl Acad Sci USA 2006;103:2689-2694.
50. Thornburg NJ, Kulwichit W, Edwards RH, et al. LMP1 signaling and activation of NF-kappaB in LMP1 transgenic mice. Oncogene 2006;25:288-297.
51. Everly Jr DN, Mainou BA, Raab-Traub N. Induction of Id1 and Id3 by latent membrane protein 1 of Epstein-Barr virus and regulation of p27/Kip and cyclin-dependent kinase 2 in rodent fibroblast transformation. J Virol 2004;78:13470-13478.
52. Qiu K, Tomita Y, Hashimoto M, et al. Epstein-Barr virus in gastric carcinoma in Suzhou, China and Osaka, Japan: association with clinico-pathologic factors and HLA-subtype. Int J Cancer 1997;71:155-158.
53. Chu PG, Chang KL, Chen WG, et al. Epstein-Barr virus (EBV) nuclear antigen (EBNA)-4 mutation in EBV-associated malignancies in three different populations. Am J Pathol 1999;155:941-947.
54. Koriyama C, Shinkura R, Hamasaki Y, et al. Human leukocyte antigens related to Epstein-Barr virus-associated gastric carcinoma in Japanese patients. Eur J Cancer Prev 2001;10:69-75.
55. Lee MA, Hong YS, Kang JH, et al. Detection of Epstein-Barr virus by PCR and expression of LMP1, p53, CD44 in gastric cancer. Korean J Intern Med 2004;19:43-47.
56. Sugiura M, Imai S, Tokunaga M, et al. Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells. Br J Cancer 1996;74:625-631.
57. Iwakiri D, Eizuru Y, Tokunaga M, et al. Autocrine growth of Epstein-Barr virus-positive gastric carcinoma cells mediated by an Epstein-Barr virus-encoded small RNA. Cancer Res 2003;63:7062-7067.
58. Lopes V, Young LS, Murray PG. Epstein-Barr virus-associated cancers: aetiology and treatment. Herpes 2003;10:78-82.
59. Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein-Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006;108:2942-2949.
60. Kenney S, Theodore E. Woodward award: development of novel, EBV-targeted therapies for EBV-positive tumors. Trans Am Clin Climatol Assoc 2006;117:55-74.
61. Schwarzmann F, Jager M, Prang N, et al. The control of lytic replication of Epstein-Barr virus in B lymphocytes (Review). Int J Mol Med 1998;1:137-142.
62. Laichalk LL, Thorley-Lawson DA. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol 2005;79:1296-1307.
63. Hong GK, Kumar P, Wang L, et al. Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J Virol 2005;79:13984-13992.
64. Feng WH, Israel B, Raab-Traub N, et al. Chemotherapy induces l ytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res 2002;62:1920-1926.
65. Feng WH, Westphal E, Mauser A, et al. Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors. J Virol 2002;76:10951-10959.
66. Feng WH, Hong G, Delecluse HJ, et al. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol 2004;78:1893-1902.
67. Koriyama C, Akiba S, Itoh T, et al. Prognostic significance of Epstein-Barr virus involvement in gastric carcinoma in Japan. Int J Mol Med 2002;10:635-639.
68. Lo YM, Chan WY, Ng EK, et al. Circulating Epstein-Barr virus DNA in the serum of patients with gastric carcinoma. Clin Cancer Res 2001;7:1856-1859.